ADVA
19.3.2020 09:03:05 CET | Business Wire | Press release
ADVA (FSE: ADV) and NEC Corporation (NEC; TSE: 6701) today announced that Viettel, a global telecommunications service provider based in Vietnam, has deployed ADVA’s Oscilloquartz timing solution throughout Laos and Myanmar to provide nationwide 4G services and prepare its synchronization network for 5G. The technology enables Viettel to smoothly transition its legacy timing infrastructure, deliver 4G coverage to more mobile subscribers and lay the foundations for next-generation services. Installed and maintained by NEC, the new solution is built on ADVA’s OSA 3230B primary reference cesium clock (PRC) for assured and precise synchronization with or without GNSS. It also features ADVA’s versatile ultra-compact synchronization supply units (SSUs) with high-capacity PTP modules for grandmaster clock functionality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005023/en/
“This deployment enables the end-to-end distribution of assured, precise and highly reliable timing. It utilizes our OSA 3230B PRC for superb accuracy with the smallest size and power footprint, as well as our ultra-scalable SSUs. With this solution, we’ve empowered Viettel to address all its most urgent synchronization needs, helped it protect past investments and opened the door to further expansion,” commented Erik Lindberg, VP, sales, APAC, ADVA. “Our close collaboration with NEC was key to the success of this project. It’s a relationship based on a great deal of trust and a shared passion to push the boundaries of possibility. And that partnership is now delivering valuable results for service providers across East Asia.”
Viettel’s new solution leverages the OSA 3230B PRC, a high-performance cesium time source that offers superior accuracy and stability together with operational simplicity and unrivalled flexibility. With its space-saving and environmentally hardened design, it fits seamlessly into a wide range of locations. Also key to the deployment were ADVA’s highly flexible Oscilloquartz SSUs, which enable Viettel to maintain its legacy synchronization networks and evolve ultra-precise, highly reliable timing to meet the requirements of time-sensitive applications and 5G connectivity. All elements of the new timing solution are overseen from Viettel’s headquarters in Vietnam using ADVA’s Ensemble Controller with Sync Director . With its highly intuitive GUI, this advanced management platform guarantees flexibility, cost-effective operations and complete centralized control.
“We’re extremely pleased to be working with our global partner, ADVA, and helping Viettel to achieve its ambitions of taking its timing infrastructure in Laos and Myanmar to the next level. By harnessing the most advanced innovation and our ongoing support, Viettel is ensuring unprecedented levels of precision and reliability as it tackles demand for low-latency services from its mobile customers,” said Mayuko Tatewaki, general manager, service provider division, NEC Corporation. “At NEC, we know the value of synchronization with strict precision. It’s one of the key components when designing 5G-ready networks. Now Viettel has a future-proof timing solution controlled by a single management system and is able to deliver phenomenally accurate phase and frequency alignment all the way from the radio base station to the core.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society. Under the company’s corporate message of “Orchestrating a brighter world,” NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at www.nec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005023/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom